Plain-English translation of NCT07265297 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called hydroxychloroquine can help treat a condition called steatohepatitis—a type of fatty liver disease where the liver becomes inflamed. Researchers want to find out if this medication works better than a placebo (a dummy pill with no active ingredient) and whether it's safe to take.
Fatty liver disease with inflammation is a growing health problem that can lead to serious liver damage if left untreated. Currently, there are limited treatment options available, so researchers are testing this medication to see if it could offer patients a new way to manage and improve their condition.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take a daily pill for 12 months—either the test medication at one of two different doses, or a placebo. You'll visit the clinic every 3 months for checkups and blood tests so researchers can monitor how your liver is responding. The study compares how well the medication works compared to placebo.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Taiwan
Large-scale testing
Sponsor
National Taiwan University Hospital
Enrollment target
~210 participants
Started
August 2025
Primary completion
December 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tsai, Doctor
National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.